Skin News

Monday, October 20, 2008 Gleevec/CYC Combo Emerging as Novel Approach for Scleroderma Lung Disease
Adding the oncology drug imatinib (Gleevec^®) to cyclophosphamide offers a 2-pronged strategy that might be effective in scleroderma-associated pulmonary complications...

Wednesday, October 15, 2008 Genentech Issues Dear Healthcare Provider Letter Regarding Case of PML in a Psoriasis Patient Under Long-Term Treatment With Raptiva^®
The 70-year old patient had received Raptiva^® (efalizumab) for >4 years to treat chronic plaque psoriasis before being diagnosed with progressive multifocal leukoencephalopathy...

Wednesday, October 08, 2008 Incyte's Topical JAK Inhibitor Shows Positive Proof-of-Concept Results in Two Phase IIa Clinical Trials in Patients with Mild-to-Moderate Psoriasis; Phase IIb Expected to Start October 2008
Results from the first study demonstrated that INCB18424 was well tolerated at all doses and significantly improved overall total lesion score (erythema + scaling + thickness)...

Monday, September 29, 2008 Abbott Reports Continuous Treatment With Humira^® Achieves Superior Long-Term Efficacy for Psoriasis Patients in the US and Europe Versus Interrupting Treatment
The findings were from the company's pivotal 52-week REVEAL study and the period of open-label treatment that followed...

Thursday, September 25, 2008 Centocor’s Ustekinumab Demonstrates Superior Efficacy to Enbrel^® (Etanercept) in Treatment of Moderate-to-Severe Plaque Psoriasis
Greater proportion of patients receiving ustekinumab achieved significant skin clearance versus patients receiving Enbrel...

Friday, September 12, 2008 BioCryst Reports Results From Phase IIa Trial of PNP Inhibitor in Psoriasis; No Evidence of Clinical Efficacy
BCX-4208 is a potent, rationally-designed, inhibitor of PNP—a purine salvage pathway enzyme that is essential for the proliferation of activated T-cells...

Tuesday, August 26, 2008 After Fits and Starts, New Hope for Psoriasis Patients
Psoriasis patients are finally finding some relief with a new wave of drug treatments known as biologics…

Thursday, August 21, 2008 Wrinkle Removers, Backed by Science
Scientific evidence has emerged that three anti-aging treatments are clinically effective: topical application of retinol, carbon dioxide resurfacing, and injection of hyaluronic acid…

Tuesday, August 19, 2008 Centocor Says US FDA Extends Review by 3 Months for Ustekinumab’s (CNTO 1275) Biologic License Application to Treat Plaque Psoriasis
Centocor filed an application with the FDA for ustekinumab in late 2007 seeking approval to market the drug to treat adult patients with chronic moderate-to-severe plaque psoriasis...

Monday, August 18, 2008 MedImmune, Medarex Report Initiation of Phase IIa Clinical Trial of Fully Human Anti-Interferonα Monoclonal Antibody in Lupus Patients
MedImmune has initiated enrollment in a phase IIa trial with a human monoclonal antibody (MEDI-545) targeting interferonα in adult patients with moderate-to-severe active lupus...